Stevens-Johnson syndrom og toksisk epidermal nekrolyse
Sist revidert:
Sist revidert av:Terje JohannessenDefinisjon:
Akutt, livstruende hudsykdom som viser seg ved utbredt erytrodermi, løsning av epidermis og mukosa ledsaget av feber og varierende grad av organinvolvering - oftest legemiddelindusert.
Forekomst:
Insidensen, inklusive Stevens-Johnson syndrom, angis å være ca. 4-7 tilfeller per 1 million innbyggere per år.
Symptomer:
Begynner ofte med prodromer i form av feber og influensalignende symptomer, og ubehag i slimhinner og øyne.
Funn:
Etter 1-3 dager kommer et utslett i ansiktet, på halsen og de sentrale deler av kroppen med et rødt og meslingeliknende utslett som raskt brer seg utover ekstremitetene, og som fører til blemmedannelse og flekkvis løsning av huden.
Diagnostikk:
Klinisk diagnose. Hudstansebiopsi kan bekrefte diagnosen.
Behandling:
Seponering av utløsende medikament og generell intensivbehandling.
- Bygum A, Andersen KE. Toksisk epidermal nekrolyse. Ugeskr Læger 2006; 168: 2645-9. PubMed
- High WA. Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis. UpToDate, last updated Mar 12, 2019. UpToDate
- Cohen V. Toxic epidermal necrolysis. Medscape, last updated Dec 20, 2018. emedicine.medscape.com
- Letko E, Papaliodis DN, Papaliodis GN et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 2005; 94: 419-36. PubMed
- Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14: 1343. pmid:19029983 PubMed
- Caproni M, Torchia D, Schincaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 2006; 155: 722. pmid:16965421 PubMed
- Kridin K, Brüggen M-C, Chua S-L, et al. Assessment of Treatment Approaches and Outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Insights From a Pan-European Multicenter Study. JAMA Dermatol 2021; 157: 1182-90. pmid:34431984 PubMed
- de Prost N, Ingen-Housz-Oro S, Duong Ta, et al. Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore) 2010; 89:28. PubMed
- Morales ME, Purdue GF, Verity SM, et al. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN. Am J Ophthalmol 2010; 150:505. PubMed
- de Prost N, Mekontso-Dessap A, Valeyrie-Allanore L, et al. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med 2014; 42:118. PubMed
- Jha AK, Goenka MK. Colonic involvement in Stevens-Johnson syndrome: a rare entity. Dig Endosc 2012; 24:382. PubMed
- Chave TA, Mortimer NJ, Sladden MJ et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005; 153: 241-53. PubMed
- Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 2013; 133:1197. PubMed
- High WA. Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae. UpToDate, last updated Sep 27, 2021. UpToDate
- Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol 2012; 167: 424-32. PubMed
- Zárate-Correa LC, Carrillo-Gómez DC, Ramírez-Escobar AF, Serrano-Reyes C. Toxic epidermal necrolysis successfully treated with infliximab. J Investig Allergol Clin Immunol 2013; 23:61. PubMed
- Paradisi A, Abeni D, Bergamo F, et al. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol 2014; 71:278. PubMed
- Terje Johannessen, professor i allmennmedisin, Trondheim